Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers

Gotoh Kiyotoshi Gotoh, Gouchi Akira Gouchi, Akura Yosikazu Akura, Tanaka Noriaki Tanaka, Orita Kunzo Orita

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Lymphocyte infiltration into a tumor has been regarded as an expression of host immunity against cancer, but tumor-infiltrating lymphocytes (TIL) have little or no cytotoxicity. This study examined two different approaches to augment this low cytotoxicity. Firstly, biological response modifiers (OK-432, PSK) were injected into gastric cancer intralesionally. Intralesional injection of OK-432 or PSK significantly augmented the cytotoxicity of TIL. By the injection of OK-432, the ratio of OKT8-, Leu7-positive cells were increased in the TIL subset. In the second approach, TIL of gastric or pulmonary cancer patients were cultured with interleukin-2 (IL-2) in vitro. Co-culturing with IL-2 augmented the low cytotoxicity of TIL, and broad-reactive lymphokine-activated killer (LAK) cells were generated from TIL.

Original languageEnglish
Pages (from-to)485-492
Number of pages8
JournalInternational Journal of Immunopharmacology
Volume13
Issue number5
DOIs
Publication statusPublished - 1991

Fingerprint

Tumor-Infiltrating Lymphocytes
Immunologic Factors
Picibanil
Stomach Neoplasms
Interleukin-2
Intralesional Injections
Lymphokine-Activated Killer Cells
Lymphocyte Subsets
Immunity
Lung Neoplasms
Neoplasms
Lymphocytes
Injections

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Kiyotoshi Gotoh, G., Akira Gouchi, G., Yosikazu Akura, A., Noriaki Tanaka, T., & Kunzo Orita, O. (1991). Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers. International Journal of Immunopharmacology, 13(5), 485-492. https://doi.org/10.1016/0192-0561(91)90067-H

Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers. / Kiyotoshi Gotoh, Gotoh; Akira Gouchi, Gouchi; Yosikazu Akura, Akura; Noriaki Tanaka, Tanaka; Kunzo Orita, Orita.

In: International Journal of Immunopharmacology, Vol. 13, No. 5, 1991, p. 485-492.

Research output: Contribution to journalArticle

Kiyotoshi Gotoh, G, Akira Gouchi, G, Yosikazu Akura, A, Noriaki Tanaka, T & Kunzo Orita, O 1991, 'Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers', International Journal of Immunopharmacology, vol. 13, no. 5, pp. 485-492. https://doi.org/10.1016/0192-0561(91)90067-H
Kiyotoshi Gotoh, Gotoh ; Akira Gouchi, Gouchi ; Yosikazu Akura, Akura ; Noriaki Tanaka, Tanaka ; Kunzo Orita, Orita. / Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers. In: International Journal of Immunopharmacology. 1991 ; Vol. 13, No. 5. pp. 485-492.
@article{56010622b78c4235b2aa46b7ea795603,
title = "Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers",
abstract = "Lymphocyte infiltration into a tumor has been regarded as an expression of host immunity against cancer, but tumor-infiltrating lymphocytes (TIL) have little or no cytotoxicity. This study examined two different approaches to augment this low cytotoxicity. Firstly, biological response modifiers (OK-432, PSK) were injected into gastric cancer intralesionally. Intralesional injection of OK-432 or PSK significantly augmented the cytotoxicity of TIL. By the injection of OK-432, the ratio of OKT8-, Leu7-positive cells were increased in the TIL subset. In the second approach, TIL of gastric or pulmonary cancer patients were cultured with interleukin-2 (IL-2) in vitro. Co-culturing with IL-2 augmented the low cytotoxicity of TIL, and broad-reactive lymphokine-activated killer (LAK) cells were generated from TIL.",
author = "{Kiyotoshi Gotoh}, Gotoh and {Akira Gouchi}, Gouchi and {Yosikazu Akura}, Akura and {Noriaki Tanaka}, Tanaka and {Kunzo Orita}, Orita",
year = "1991",
doi = "10.1016/0192-0561(91)90067-H",
language = "English",
volume = "13",
pages = "485--492",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers

AU - Kiyotoshi Gotoh, Gotoh

AU - Akira Gouchi, Gouchi

AU - Yosikazu Akura, Akura

AU - Noriaki Tanaka, Tanaka

AU - Kunzo Orita, Orita

PY - 1991

Y1 - 1991

N2 - Lymphocyte infiltration into a tumor has been regarded as an expression of host immunity against cancer, but tumor-infiltrating lymphocytes (TIL) have little or no cytotoxicity. This study examined two different approaches to augment this low cytotoxicity. Firstly, biological response modifiers (OK-432, PSK) were injected into gastric cancer intralesionally. Intralesional injection of OK-432 or PSK significantly augmented the cytotoxicity of TIL. By the injection of OK-432, the ratio of OKT8-, Leu7-positive cells were increased in the TIL subset. In the second approach, TIL of gastric or pulmonary cancer patients were cultured with interleukin-2 (IL-2) in vitro. Co-culturing with IL-2 augmented the low cytotoxicity of TIL, and broad-reactive lymphokine-activated killer (LAK) cells were generated from TIL.

AB - Lymphocyte infiltration into a tumor has been regarded as an expression of host immunity against cancer, but tumor-infiltrating lymphocytes (TIL) have little or no cytotoxicity. This study examined two different approaches to augment this low cytotoxicity. Firstly, biological response modifiers (OK-432, PSK) were injected into gastric cancer intralesionally. Intralesional injection of OK-432 or PSK significantly augmented the cytotoxicity of TIL. By the injection of OK-432, the ratio of OKT8-, Leu7-positive cells were increased in the TIL subset. In the second approach, TIL of gastric or pulmonary cancer patients were cultured with interleukin-2 (IL-2) in vitro. Co-culturing with IL-2 augmented the low cytotoxicity of TIL, and broad-reactive lymphokine-activated killer (LAK) cells were generated from TIL.

UR - http://www.scopus.com/inward/record.url?scp=0025740498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025740498&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(91)90067-H

DO - 10.1016/0192-0561(91)90067-H

M3 - Article

C2 - 1783460

AN - SCOPUS:0025740498

VL - 13

SP - 485

EP - 492

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 5

ER -